1261493-54-2 Usage
General Description
2-Chloro-4,6-difluorobenzaldehyde is a chemical compound with the molecular formula C7H3ClF2O. It is an aromatic aldehyde with a chlorine atom and two fluorine atoms attached to a benzene ring. 2-chloro-4,6-difluorobenzaldehyde is used as a building block in organic synthesis and can be utilized in the production of various pharmaceuticals, agrochemicals, and dyes. Its chemical structure and reactivity make it a valuable intermediate in the development of new chemical compounds. Additionally, it is important to handle this compound with care as it may pose a hazard to human health and the environment if not properly managed.
Check Digit Verification of cas no
The CAS Registry Mumber 1261493-54-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,1,4,9 and 3 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1261493-54:
(9*1)+(8*2)+(7*6)+(6*1)+(5*4)+(4*9)+(3*3)+(2*5)+(1*4)=152
152 % 10 = 2
So 1261493-54-2 is a valid CAS Registry Number.
1261493-54-2Relevant articles and documents
Pd-Catalyzed, ortho C-H Methylation and Fluorination of Benzaldehydes Using Orthanilic Acids as Transient Directing Groups
Chen, Xiao-Yang,Sorensen, Erik J.
supporting information, p. 2789 - 2792 (2018/03/08)
The direct, Pd-catalyzed ortho C-H methylation and fluorination of benzaldehydes have been accomplished using commercially available orthanilic acids as transient directing groups. In these reactions, the 1-fluoro-2,4,6-trimethylpyridinium salts can be either a bystanding F+ oxidant or an electrophilic fluorinating reagent. An X-ray crystal structure of a benzaldehyde ortho C-H palladation intermediate was obtained using triphenylphosphine as the stabilizing ligand.
OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 81, (2014/01/18)
The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
